OCULAR THERAPEUTIX INC (OCUL)
Health Care · biotechnology · NASDAQ
Ocular Therapeutix develops sustained-release, bioresorbable hydrogel-based ocular therapies to address chronic and acute eye diseases.
What OCULAR THERAPEUTIX INC does
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of ophthalmic therapies using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX. Its primary marketed product is DEXTENZA, a corticosteroid insert for ocular inflammation and pain, while its late-stage pipeline focuses on treatments for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
Themes: ophthalmology, drug delivery systems, wet AMD, diabetic retinopathy, sustained-release formulations
Fundamentals
- Price$7.51 as of 2026-10-08 close
- Market cap$1.6B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-36.9% 2025-10-08 close $11.91 → 2026-10-08 close $7.51
- P/En/a negative earnings
- Net margin-511.9% FY2025, SEC XBRL
- ROE-40.6% FY2025, SEC XBRL
- Debt / equity0.14 as of 2026-09-02
- Revenue growth (YoY)-8.1% as of 2026-09-02
- Revenue CAGR (3y)+0.3% SEC XBRL
- Beta1.35 as of 2026-09-02
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How OCUL compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
OCUL is not currently in any published Top 10 list. Its scores are below.
Top 10 score
23.6 #1389 of 1,398 scored · #155 of 155 in Health Care
Valuation 42nd (price to book 4.1) and financial health 40th (debt to equity 0.1, free cash flow margin -417.5%); weakest is profitability (3rd, operating margin -519.8%, return on equity -40.6%).
Scores as of 25 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. OCUL was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How OCULAR THERAPEUTIX INC looks technically
OCULAR THERAPEUTIX INC (OCUL) is trading 21.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 54.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 21.3% below its 200-day average, the long-term trend line — a long-term downtrend | -21.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $9.67 | $9.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.55 | $9.55 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 11.48. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal | 10 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control | 32.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 34.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($6.79 to $10.61) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.44 | $16.44 |
|---|---|---|
| From the 52-week high | it is 54.3% below its 52-week high (its highest price of the past year) | -54.3% |
| Above the 52-week low | it is 20.5% above its 52-week low (its lowest price of the past year) | +20.5% |
| Below the 52-week high | it is 54.3% below its highest point of the past year | 54.3% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $44.19 (set on 2015-03-25) | $44.19 |
| Given back of the 52-week move | over the past year its closes ranged ($6.88 to $16.11), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.58 to $12.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.8% |
| From the all-time high | it is 83.0% below its all-time high | -83.0% |
| Nearest price level | it is trading 8.3% below a resistance level at $8.13 — a price it turned at six times since 2024-11-21, most recently on 2026-07-31. Since 2024-10-08 it has 1 such level below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +8.3% |
| All-time low | its lowest closing price on record is $2.00 (set on 2023-11-10) | $2.00 |
| Above the all-time low | it is 276.4% above its all-time low | +276.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5791 between its high and its low — about 7.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5791 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.15 and $11.66 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.15 – $8.91 – $11.66 |
| Typical daily range (% of price) | its price moves about 7.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.7% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges below its 200-day average price (21.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.25× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.8% below the previous close 8 sessions ago and has not traded back through the level it left behind at 9.65 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.8% |
| Gap filled | a 2.4% gap up opened on 2026-09-17 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 13 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 35.0 percentage points (the stock lost 33.9% while the market gained 1.0%) | -35.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 30.7 percentage points (the stock lost 26.9% while the market gained 3.8%) | -30.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.4 percentage points (the stock lost 6.9% while the market gained 17.5%) | -24.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 51.9 percentage points (the stock lost 36.9% while the market gained 15.0%) | -51.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.2% of the share price. | -24.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.25 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -18.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.38 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -19.9% |
Price levels it has turned at before
OCUL last closed at $7.51 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 13 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.13 | Resistance | 8.3% above the last close | turned there six times · 2024-11-21 to 2026-07-31 |
| $8.33 | Resistance | 10.9% above the last close | turned there twice · 2025-02-05 to 2026-02-03 |
| $8.91 | Resistance | 18.6% above the last close | turned there twice · 2025-03-12 to 2025-05-02 |
| $5.79 | Support | 22.9% below the last close | turned there twice · 2025-03-04 to 2025-04-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $11.48.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 17 trading days, since 2026-09-16.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · lagging the market · Printed a bullish engulfing pair · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$27.09 range $18.00 – $34.00; median $28.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OCUL
- Consensus EPS estimate-$0.352 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 from -$0.352, on 2026-08-30, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and uncertainty regarding future profitability and capital requirements.","Dependence on the success of late-stage clinical candidates like AXPAXLI.","Exposure to litigation and intellectual property disputes."]
What changed in the latest 10-Q
AI-assisted comparison of OCUL's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- February 2026 announcement of positive topline Week 52 results for SOL-1 trial (newer filing)
- Description of AXPAXLI as 'bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties' (newer filing)
- Reference to HELIOS program as Phase 3 registrational program for diabetic retinal disease including NPDR (newer filing)
- Statement that SOL-1 trial completed randomization 'In December 2024' with explicit date reference (newer filing)
- Detailed enrollment screening criteria including CSFT and BCVA thresholds (newer filing)
- Description of loading dose administration 'between the screening visit and Day 1: one at Week -8 and another at Week -4' with 'Between' language (newer filing)
- Specific statement on retention: 'greater than 95% of randomized subjects remaining on trial to date' (newer filing)
- Statement that 'All subjects have completed their Week 52 visit and have been re-dosed according to their baseline treatment assignment' (newer filing)
- Primary endpoint results: 74.1% vs 55.8% with risk difference 17.5% and p-value 0.0006 (newer filing)
- Key secondary endpoint results at Week 52: 65.9% vs 44.2% with risk difference 21.1% and p-value <0.0001 (newer filing)
- Safety overview statement: 'No treatment-related ocular or systemic serious adverse events were observed' (newer filing)
- Statement on masking duration: 'Trial subjects and designated trial personnel will remain masked through the end of Week 104' (newer filing)
- Week 52 database lock date of February 5, 2026 (newer filing)
- Removed:
- Description of AXPAXLI as 'axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology' (older filing)
- Statement that NPDR Phase 3 program was 'planned to be initiated imminently' (older filing)
- Description of OTX-TIC as 'investigational product candidate' (older filing)
- Statement that company is 'currently evaluating next steps for the OTX-TIC program' (older filing)
- Statement 'We are currently conducting the SOL-1 trial' (older filing)
- Reference to 'active macular choroidal neovascularization at screening' as enrollment descriptor (older filing)
- Statement that 'After screening, enrolled subjects received two aflibercept 2 mg loading doses' (older filing)
- Language 'Subjects reaching either...' for randomization criteria without 'on Day 1' reference (older filing)
- Statement that 'are re-dosed' at Weeks 52 and 76 (older filing)
- Shorter retention statement: 'greater than 95% of randomized subjects remaining on-trial to date' (older filing)
- Statement that 'rescues reviewed under masking shows greater than 95% of rescue events' (older filing)
- Expected timeline statement: 'We continue to expect topline results for the SOL-1 trial to be available in the first quarter of 2026' (older filing)
- Entire SOL-R Trial subsection (older filing)
- Safety until 'end of Year 2' language (older filing)
- Reworded:
- Changed from 'AXPAXLI (also known as OTX-TKI), our investigational product candidate for retinal disease' to 'AXPAXLI, also known as OTX-TKI, our investigational, bioresorbable, intravitreal hydrogel incorporating axitinib'
- Changed from 'We are currently conducting' to 'In February 2026, we announced positive topline Week 52 results for the SOL-1 trial'
- Changed from 'planned to be initiated imminently' to 'which we refer to as the HELIOS program'
- Changed from 'in our investigational product candidate OTX-TIC' to 'in our product candidate OTX-TIC'
- Changed from 'We are currently evaluating next steps' to 'We are evaluating next steps'
- Changed description of diagnoses from 'active macular choroidal neovascularization at screening' to 'a diagnosis of wet AMD in the study eye at screening'
- Changed from 'After screening, enrolled subjects received' to 'After initial screening, every enrolled subject received'
- Changed from 'were randomized in the trial' to 'were randomized in the trial on Day 1 (Baseline)'
- Changed from 'Retention in the trial continues' to 'Retention in the SOL-1 trial continues'
- Changed from 'rescues reviewed under masking shows' to 'rescues reviewed under masking show'
- Changed 'maintain visual acuity' to 'maintained visual acuity' in results context
- Changed from 'are re-dosed' to 'are eligible to be re-dosed'
- Changed from 'Subjects will be followed for safety until the end of Year 2' to 'Subjects will be followed for safety until the end of Week 104'
- Changed description of secondary endpoint from 'One of the secondary endpoints being evaluated' to 'One of the key secondary endpoints'
- Notes:
- The older filing text is truncated at the end and does not include the complete SOL-R Trial section
- The newer filing is also truncated at the safety overview section and does not include complete safety data
- Comparison is limited to the extent of provided text passages
Risk Factors
- Added:
- Newer filing (2026-05-05) adds reference to 'registrational clinical trials' as descriptor for ongoing trials
- Newer filing (2026-05-05) adds specific mention of 'SOL-X trial' as 'long-term extension study for AXPAXLI for the treatment of wet AMD'
- Newer filing (2026-05-05) adds mention of 'potential second Phase 3 clinical trial of AXPAXLI for the treatment of NPDR, which we refer to as the HELIOS-2 trial'
- Newer filing (2026-05-05) adds references to 'commercialization, marketing and manufacturing plans, capabilities and strategy'
- Newer filing (2026-05-05) adds 'the potential for us to raise additional capital' language compared to older 'our plans to raise'
- Removed:
- Older filing (2025-11-04) references 'our planned long-term extension study' which becomes 'our long-term extension study' in newer filing
- Older filing (2025-11-04) references 'our planned registrational Phase 3 clinical trials' for HELIOS-2 and HELIOS-3 which is restructured in newer filing
- Older filing (2025-11-04) states 'our plans to develop and potentially seek regulatory approval' which becomes 'our plans and strategies to develop and seek regulatory approval' in newer filing
- Reworded:
- Reorganization of clinical trial descriptions: older filing groups SOL-X, HELIOS-2, and HELIOS-3 together as 'planned' trials; newer filing separates them and designates HELIOS-2 as 'potential' while HELIOS-3 and SOL-X are presented as ongoing/committed trials
- Change from 'our commercialization efforts for our product DEXTENZA' (older, 2025-11-04) to 'our commercialization, marketing and manufacturing plans, capabilities and strategy, including our commercialization efforts for our product DEXTENZA' (newer, 2026-05-05)
- Change from 'our plans to develop and potentially seek regulatory approval' (older, 2025-11-04) to 'our plans and strategies to develop and seek regulatory approval' (newer, 2026-05-05)
- Reference to Form 10-K year changed from 'December 31, 2024' filed 'March 3, 2025' (older, 2025-11-04) to 'December 31, 2025' filed 'February 5, 2026' (newer, 2026-05-05)
- Table of Contents page numbers changed: 'Item 1A. Risk Factors' changed from page 44 to page 38; other items also adjusted
- Notes:
- The provided text excerpts appear to be Forward-Looking Statements sections rather than the actual Risk Factors sections; however, changes are factually reported from the supplied text
- Some organizational restructuring of clinical trial information may reflect updates to trial status rather than substantive new disclosures
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($147056) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 7 sells ($480137) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 12 sells ($840556) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OCUL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OCUL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 59,463,802
- Reported value $583,934,532
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OCUL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OCUL had 29,933,140 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
OCUL had 13.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.19 days to cover at the same settlement.
- Reported short interest (shares) 29,933,140
- Short interest (% of shares outstanding) 13.6%
- Prior settlement (shares) 28,055,522
- Reported change 6.69%
- Days to cover (reported) 14.19
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OCUL vs…
OCULAR THERAPEUTIX INC is found in…
Frequently asked questions
What does OCULAR THERAPEUTIX INC (OCUL) do?
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of ophthalmic therapies using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX. Its primary marketed product is DEXTENZA, a corticosteroid insert for ocular inflammation and pain, while its late-stage pipeline focuses on treatments for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
What sector is OCULAR THERAPEUTIX INC (OCUL) in?
OCULAR THERAPEUTIX INC (OCUL) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are OCULAR THERAPEUTIX INC's (OCUL) competitors?
Notable peers of OCULAR THERAPEUTIX INC (OCUL) include EyePoint Pharmaceuticals, Regeneron, Roche, Novartis and AbbVie. This peer set is informational only — not financial advice.
Is OCULAR THERAPEUTIX INC (OCUL) overbought or oversold right now?
OCULAR THERAPEUTIX INC (OCUL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OCUL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.